About: Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?
Creator	Francis, Fadi Hashash, Jana Jabak, Suha Regueiro, Miguel
source	Medline; PMC
abstract	covid:667888aa93eec1de45624e8fee1b1952a00ae9fb#abstract
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1093/ibd/izaa173
bibo:pmid	32619000
has license	no-cc
sha1sum (hex)	667888aa93eec1de45624e8fee1b1952a00ae9fb
schema:url	https://doi.org/10.1093/ibd/izaa173
resource representing a document's title	Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?
has PubMed Central identifier	PMC7337746
has PubMed identifier	32619000
schema:publication	Inflamm Bowel Dis
resource representing a document's body	covid:667888aa93eec1de45624e8fee1b1952a00ae9fb#body_text
is schema:about of	named entity 'immunosuppression' named entity 'COVID-19' named entity 'tofacitinib' named entity '1.02' named entity 'older age' named entity 'ulcerative colitis' named entity 'nucleic acid test' named entity 'anti-TNF' named entity 'antigen' named entity 'comorbid conditions' named entity 'saliva' named entity 'COVID' named entity 'risk factors' named entity 'lower respiratory tract' named entity '1.1' named entity 'SARS-CoV-2' named entity 'cytomegalovirus' named entity 'immunosuppressive' named entity 'United States' named entity 'human immunodeficiency virus' named entity 'infection' named entity 'World Health Organization' named entity 'Inflammatory bowel disease' named entity 'IBD' named entity 'cardiovascular disease' named entity 'Epstein-Barr virus' named entity 'COVID' named entity 'IBD' named entity 'necrosis' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'infection' named entity 'NAAT' named entity 'COVID' named entity 'immunosuppressive treatment' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'general population' named entity 'obesity' named entity 'biologic therapy' named entity 'general population' named entity 'SARS-CoV-2' named entity 'intravenous' named entity 'NATs' named entity 'IgM' named entity 'Inflammatory Bowel Disease' named entity 'infection' named entity 'COVID-19' named entity 'point of care' named entity 'alternative therapies' named entity 'methotrexate' named entity 'asymptomatic' named entity 'WHO' named entity 'diagnostic testing' named entity 'IBD' named entity 'infection' named entity 'biologics' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'IBD' named entity 'immunosuppressive medications' named entity '95% CI' named entity 'viral infections' named entity 'SARS-CoV-2' named entity 'biologic therapy' named entity 'biologic therapy' named entity 'bone marrow transplant' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'anti-TNF' named entity 'COVID' named entity 'serologic' named entity 'remission' named entity 'SARS-CoV-2' named entity 'vedolizumab' named entity 'COVID' named entity 'older age'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software